retatrutide clinical trial thailand ​"Triple-Hormone" Drug Shows Record Weight Loss: At the American Diabetes Association's 2026 Scientific Sessions, researchers unveiled phase 3 results for retatrutide, the first therapy to Triple hormone receptor agonist retatrutide

And like the rest of this drug class, it will raise the usual questions about long-term use, cost, access and what happens when treatment stops

As most studies have been based on short-term GIP exposure, additional research is needed to understand this relationship with chronic GIPR activation that occurs with new and emerging pharmacologic GIPRAs

As a result, the drugs might reduce the effect of alcohol and help people drink less

Semaglutide GLP-1 assists in this endeavor through: Appetite Regulation: By increasing satiety and reducing appetite, semaglutide GLP-1 helps our patients sustainably achieve their weight loss goals

Which nutrients require special attention

It is a question increasingly asked by patients and clinicians as this investigational triple receptor agonist advances through clinical trials